ARQT
NASDAQArcutis Biotherapeutics Inc.
Price$28.47+0.42 (+1.50%)
01:30 PM07:45 PM
News · 26 weeks91-27%
2026-01-182026-07-12
Mix4790d
- Insider21(45%)
- Other13(28%)
- SEC Filings9(19%)
- Earnings2(4%)
- Leadership2(4%)
Latest news
25 items- INSIDERDirector Peetz Christopher was granted 4,315 shares (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERNew insider Peetz Christopher claimed ownership of 187,500 shares (SEC Form 3)3 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERDirector Welgus Howard G. exercised 4,096 shares at a strike of $7.93 and sold $127,284 worth of shares (4,730 units at $26.91) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 37,109 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- SECArcutis Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)
- PRArcutis Expands Board of Directors with Appointment of Chris PeetzWESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today announced that Christopher "Chris" Peetz has been appointed to the Arcutis Board of Directors effective July 15, 2026. "We are delighted to welcome Chris Peetz to our Board of Directors at a pivotal time for Arcutis," said Frank Watanabe, president and chief executive officer of Arcutis. "Chris has built an impressive track record leading biopharmaceutical companies through periods of expansion, from advancing multiple products through development, to building commerci
- PRArcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026WESTLAKE VILLAGE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its second quarter 2026 financial results and provide a business update after the U.S. financial markets close on Wednesday, August 5, 2026. The Company will host a conference call and webcast at 4:30 p.m. ET that same day. A live webcast of the call and related presentation materials will be available on the "Events" section of the Company’s website. A replay of the webcast will be available on the Arcutis investor website following the c
- PRAttovia Therapeutics Appoints John W. Smither to Board of DirectorsSAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the appointment of John W. Smither to its Board of Directors as an independent director and as Chair of the Audit Committee. "We are pleased to welcome John to our Board," said Tao Fu, Founder and Chief Executive Officer of Attovia. "John is a proven leader in guiding biotechnology companies through critical stages of development. Having served as Chief Financial Officer across multiple public and private biotechnology companies,
- PRFDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 MonthsFDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label pharmacokinetic (PK) study1 million children under the age of 2 are treated topically for atopic dermatitis in the United States, representing 10% of all adults and children treated topically for atopic dermatitis WESTLAKE VILLAGE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the U.S. Food and Drug Administration (
- PRArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WESTLAKE VILLAGE, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 61,000 restricted stock units (RSUs) of Arcutis common stock to 9 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rul
- PRArcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) IndicationsVirtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasisConnects eligible individuals with independent, board-certified dermatologists through a streamlined digital experience for evaluation and to discuss potential treatment options WESTLAKE VILLAGE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the launch of a new virtual health platform designed to expand access pathways to its ZORYVE® (roflumilast) portf
- PRFDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of ageZORYVE cream 0.3% is safe, effective, and well-tolerated for use anywhere on the body with no restrictions on duration of useSeventh FDA approval for ZORYVE in four years WESTLAKE VILLAGE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to expand the indication for ZORYVE® (roflumilast)
- INSIDERDirector Lin Sue-Jean sold $120,587 worth of shares (4,946 units at $24.38) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 27,567 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERDirector Welgus Howard G. exercised 4,096 shares at a strike of $7.93 and sold $116,281 worth of shares (4,731 units at $24.58) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 37,743 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Heron Patrick J4/A - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERDirector Heron Patrick J was granted 5,778 shares, increasing direct ownership by 22% to 32,213 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERDirector Lin Sue-Jean was granted 5,778 shares, increasing direct ownership by 22% to 32,513 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERDirector Welgus Howard G. was granted 5,778 shares, increasing direct ownership by 18% to 38,378 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERDirector Leonard Keith R was granted 5,778 shares, increasing direct ownership by 26% to 27,901 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERDirector Curran Terrie was granted 5,778 shares, increasing direct ownership by 33% to 23,526 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERDirector Munshi Amit was granted 5,778 shares, increasing direct ownership by 144% to 9,799 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERDirector Krishnamohan Neha was granted 5,778 shares, increasing direct ownership by 26% to 27,901 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERDirector Gilbert Halley E was granted 5,778 shares, increasing direct ownership by 26% to 27,901 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- SECArcutis Biotherapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)
- PRArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 44,000 restricted stock units of Arcutis' common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of June 1, 2026, as a material inducement to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted st
- PRNew Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical DermatologyExpert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populationsThis is the second published manuscript from the Genital Psoriasis Wellness Consortium, a multidisciplinary group of expert cliniciansGenital involvement occurs in approximately two-thirds of the nine million individuals with plaque psoriasis in the United States WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the publication of a new manuscript in the Ameri
ARQT FAQ
7 questionsWhat does Arcutis Biotherapeutics Inc. do?
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252...Where does ARQT stock trade?
Arcutis Biotherapeutics Inc. (ARQT) is listed on NASDAQ.What sector and industry is ARQT in?
Arcutis Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Arcutis Biotherapeutics Inc. go public?
Arcutis Biotherapeutics Inc. (ARQT) completed its IPO in 2020.What are analysts saying about ARQT?
Arcutis Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Neutral with a $1800.00 price target on 2025-07-25.What companies are similar to ARQT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ARQT side-by-side with any of them on Quantisnow.How can I track ARQT on Quantisnow?
Quantisnow aggregates Arcutis Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARQT to receive live email and push alerts on every new disclosure.